NHS to pay 25% more for innovative drugs after UK–US zero-tariff deal

Key Highlights

• The UK will pay 25% more for new medicines by 2035.
• The NHS's spending on innovative therapies will double from 0.3% to 0.6% of GDP over the next decade.
• UK pharmaceutical exports to the US, worth at least £5 billion a year, will be tariff-free for three years.
• The agreement aims to protect jobs and boost investment in the UK pharmaceutical sector.
• This deal follows threats from the US to impose tariffs as high as 100% on UK drug imports.